A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDMI patients

Diabetes Care

Volumn 19, Issue 3, 1996, Pages 252-254

  Bayraktar, Miyase ^a   Van Thiel, David H ^a   Adalar, Nezaket ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; C PEPTIDE; CHOLESTEROL; FIBRINOGEN; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET THERAPY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACARBOSE; ADULT; BLOOD GLUCOSE; C-PEPTIDE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TRIGLYCERIDES; TRISACCHARIDES;

EID: 0030070954     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.3.252     Document Type: Article

References (13)

1. Lebowitz HE, Pasmantier R: Combination insulin-sulfonylurea therapy. Diabetes Care 13:667-675, 1990
2. Hanefield M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fucker K: Therapeutic potentials of acarbose as first-line drug in NIDDM patients insufficiently treated with diet alone. Diabetes Care 14:732-737, 1991
3. Gerard J, Luyckx A, Lefebvre P: Improvement of metabolic control in insulin dependent diabetics treated with α-glucosidase inhibitor acarbose for two months. Diabetologia 21:446-451, 1981
4. Buchanan DR, Collier SA, Caspary WF, Rodrigues E, Millar AM, Gray RS, Clark BF: Effectiveness of acarbose, an alpha-glucosidase inhibitor, m uncontrolled non-obese insulin dependent diabetes. Eur J Clin Pharmacol 34:51-53, 1988
5. Nattras M, Hinks L, Smythe P, Tooa PG, Alberti KGMM: Metabolic effects of combined sulfonylurea and metformin therapy in maturity-onset diabetics Horm Metab Res 11:332-337, 1979
6. Hermann LS: Biguanides and sulfonylureas as combination therapy m NIDDM. Diabetes Care 13 (Suppl. 3):37-41, 1990
7. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ: Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly con trolled by sulfonylureas. Diabetes Care 13 (Suppl. 3):32-36, 1990
8. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A: Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 17:1100-1109, 1994
9. Trischitta V, Italia S, Mazzarino S, Buscema M, Rabuazzo AM, Sangiorgio L, Squatrito S, Vigneri R Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care 15:539-542, 1992
10. Reaven GM, Johnston P, Hollenbeck CB, Skowronski R, Zhang JC, Goldfine ID, Chen YD Combined metformin-sulfonylurea treatment of patients with non-insulin dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 74:1020-1026, 1992
11. Marena S, Tagliaferro V, Montegrosso G, Pagano A, Scaglione L, Pagano G: Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabete Metab 20: 15-19, 1994
12. Vignen R, Goldfine ID: Role of metformin in treatment of diabetes mellitus Diabetes Care 10:118-121, 1987
13. Zimmerman BR: Preventing long-term complications: implications for combination therapy with acarbose Drugs 44 (Suppl. 3).54-60, 1992